Phase 3 Trials of Its First Indigenous Dengue Vaccine
Kartavya Desk Staff
Source: BT
Context: India has enrolled over 8,000 participants in Phase 3 trials of its first indigenous dengue vaccine, developed by Panacea Biotec and supported by ICMR.
About Phase 3 Trials of Its First Indigenous Dengue Vaccine:
• What Is India’s First Dengue Vaccine? Name: DengiAll – a tetravalent dengue vaccine designed to protect against all four dengue virus serotypes (DENV-1 to DENV-4). Origin: Derived from the TV003/TV005 strain originally developed by the U.S. National Institutes of Health (NIH) and licensed to Indian firms.
• Name: DengiAll – a tetravalent dengue vaccine designed to protect against all four dengue virus serotypes (DENV-1 to DENV-4).
• Origin: Derived from the TV003/TV005 strain originally developed by the U.S. National Institutes of Health (NIH) and licensed to Indian firms.
• Organisations Involved: ICMR (Indian Council of Medical Research): Primary funder and scientific lead. Panacea Biotec: Vaccine developer holding process patents and leading formulation trials.
• ICMR (Indian Council of Medical Research): Primary funder and scientific lead.
• Panacea Biotec: Vaccine developer holding process patents and leading formulation trials.
• How It Works? Tetravalent nature: Offers immunity against all four dengue strains, reducing chances of reinfection. Live-attenuated virus: Introduces weakened viruses to safely trigger immune response. Two-dose vaccine: Participants receive doses followed by two years of medical follow-up to assess efficacy.
• Tetravalent nature: Offers immunity against all four dengue strains, reducing chances of reinfection.
• Live-attenuated virus: Introduces weakened viruses to safely trigger immune response.
• Two-dose vaccine: Participants receive doses followed by two years of medical follow-up to assess efficacy.
• Key Features: Pan-India Coverage: Trials being conducted at 20 centres including Chennai, Pune, Delhi, Hyderabad. Large-Scale Participation: Nearly 80% enrolment completed out of 10,000 targeted candidates. Process Patented: Panacea holds proprietary rights over vaccine formulation. Previous Trial Success: Phase 1 and 2 completed in 2018–19 with encouraging results. Clinical Vigilance: Participants to be monitored for two years post-vaccination
• Pan-India Coverage: Trials being conducted at 20 centres including Chennai, Pune, Delhi, Hyderabad.
• Large-Scale Participation: Nearly 80% enrolment completed out of 10,000 targeted candidates.
• Process Patented: Panacea holds proprietary rights over vaccine formulation.
• Previous Trial Success: Phase 1 and 2 completed in 2018–19 with encouraging results.
• Clinical Vigilance: Participants to be monitored for two years post-vaccination
• Significance for India: Public Health Impact: Addresses one of India’s most widespread mosquito-borne illnesses. Child Health Focus: Offers critical protection for children, who face higher hospitalisation risk. Reduces Repeat Infections: Crucial due to low cross-protection between dengue serotypes.
• Public Health Impact: Addresses one of India’s most widespread mosquito-borne illnesses.
• Child Health Focus: Offers critical protection for children, who face higher hospitalisation risk.
• Reduces Repeat Infections: Crucial due to low cross-protection between dengue serotypes.